BMC Health Services Research · 2020 · 19 citations · 19 references
Public AffairsInfectious DiseasesPharmacoeconomicsCost-benefit AnalysisImmunizationVaccinologyAdverse Events Following ImmunizationImmunization PolicyVaccinationVaccination PolicyVaccine PolicyVaccine SafetyCost-effectiveness Of VaccinationCost-minimization Analysis PerspectiveInactivated Polio VaccineOral Polio VaccinationSocietal Perspective AnalysisTotal Cost MinimizationVaccination EconomicsVaccination Policy Evaluation
BACKGROUND: The phased withdrawal of oral polio vaccine (OPV) and the introduction of inactivated poliovirus vaccine (IPV) is central to the polio 'end-game' strategy. METHODS: We analyzed the cost implications in Chile of a switch from the vaccination scheme consisting of a pentavalent vaccine with whole-cell pertussis component (wP) plus IPV/OPV vaccines to a scheme with a hexavalent vaccine with acellular pertussis component (aP) and IPV (Hexaxim®) from a societal perspective. Cost data were collected from a variety of sources including national estimates and previous vaccine studies. All costs were expressed in 2017 prices (US$ 1.00 = $Ch 666.26). RESULTS: The overall costs associated with the vaccination scheme (4 doses of pentavalent vaccine plus 1 dose IPV and 3 doses OPV) from a societal perspective was estimated to be US$ 12.70 million, of which US$ 8.84 million were associated with the management of adverse events related to wP. In comparison, the cost associated with the 4-dose scheme with a hexavalent vaccine (based upon the PAHO reference price) was US$ 19.76 million. The cost of switching to the hexavalent vaccine would be an additional US$ 6.45 million. Overall, depending on the scenario, the costs of switching to the hexavalent scheme would range from an additional US$ 2.62 million to US$ 6.45 million compared with the current vaccination scheme. CONCLUSIONS: The switch to the hexavalent vaccine schedule in Chile would lead to additional acquisition costs, which would be partially offset by improved logistics, and a reduction in adverse events associated with the current vaccines.
19
Jason M. Warfel, Lindsey I. Zimmerman, Tod J. Merkel · Proceedings of the National Academy of Sciences · 2013 · 635 citations · Full text
Comparison of 13 Acellular Pertussis Vaccines: Adverse Reactions
Michael D. Decker, Kathryn M. Edwards, Mark C. Steinhoff et al. · PEDIATRICS · 1995 · 266 citations
Medicine, Child Health, Pediatrics +17